Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Laboratories adopt Digene's Hybrid Capture II HPV ( human papilloma virus) test:

This article was originally published in Clinica

Executive Summary

Diagnostic test providers Quest Diagnostics and Laboratory Corporation of America are to offer Digene's Hybrid Capture II HPV test. Gaithersburg, Maryland-based Digene's test can detect the 13 high-risk forms of HPV which are detected in over 99% of cervical cancers and is used in conjunction with the traditional Pap smear. Some 15,000 women are diagnosed with cervical cancer in the US each year. Around 5,000 women die from the condition, which affects 500,000 women worldwide, each year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073054

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel